Cosmos Health Secures 1.2M Unit Drug Deal, Bolstering European Production

CHICAGO, IL – January 05, 2026 – Cosmos Health Inc. today announced a landmark manufacturing and supply agreement that significantly expands its production footprint in Europe and promises to enhance access to a critical pain relief medication in Greece. The global healthcare group's wholly-owned subsidiary, Cana Laboratories, will undertake the complete manufacturing of PathMuscle, a modern muscle relaxant, for its exclusive Greek distributor, Libytec Pharmaceutical S.A.

The five-year agreement outlines expected cumulative production volumes anticipated to surpass 1.2 million units, with a firm minimum commitment of 591,500 units. This move not only provides Cosmos Health with substantial long-term revenue visibility but also strategically positions the company as a key contract manufacturing partner within the European Union's competitive pharmaceutical sector.

A Strategic Play in Vertical Integration

This agreement is a powerful illustration of Cosmos Health's vertically integrated business model in action. The Nasdaq-listed company, which owns a portfolio of proprietary health brands and operates in telehealth, leverages its in-house manufacturing capabilities to create powerful synergies. The deal relies on the expertise of Cana Laboratories, a Greek facility licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA)—the gold standard for pharmaceutical production in the region.

Under the terms, Cana Laboratories will manage the entire production lifecycle of PathMuscle, from initial formulation and large-scale production to stringent quality control and final product release. This end-to-end responsibility showcases the subsidiary's operational maturity and regulatory prowess. By controlling the manufacturing process, Cosmos Health can ensure quality, manage costs, and guarantee a reliable supply chain for its partner, Libytec.

Greg Siokas, CEO of Cosmos Health, emphasized the strategic importance of the collaboration. “This agreement supports our strategic focus on expanding pharmaceutical manufacturing through long-term, volume-backed collaborations,” he stated. “By assuming full responsibility for the end-to-end production of PathMuscle, Cosmos Health demonstrates its operational strength, regulatory expertise, and ability to deliver reliable, scalable manufacturing solutions. We believe this collaboration enhances production visibility and reinforces our position as a trusted manufacturing partner in the European pharmaceutical market.”

Meeting a Pressing Need for Pain Relief in Greece

The timing and focus of this agreement are particularly critical for public health in Greece. Musculoskeletal disorders (MSDs) represent a significant and widespread health burden in the country. Research has highlighted the high prevalence of these conditions, with studies indicating that over 80% of healthcare professionals, such as nurses and physiotherapists, report work-related musculoskeletal pain. Across the general adult population, conditions like low back pain, neck pain, and peripheral osteoarthritis affect a substantial percentage of citizens, driving a consistent demand for effective treatments.

PathMuscle is specifically designed to address this need. As an advanced generic pharmaceutical, it is a fixed-dose combination of two well-established active ingredients: thiocolchicoside, a centrally acting muscle relaxant, and paracetamol (acetaminophen), a widely used analgesic and antipyretic. This combination therapy offers patients the convenience of addressing both muscle spasms and associated pain in a single tablet, which can improve treatment adherence and overall quality of life. The product will be available in multiple oral presentations to suit different patient needs.

The partnership ensures that this therapy will be effectively commercialized by Libytec Pharmaceutical S.A., which will handle all distribution and promotion within the Greek market. By manufacturing the product locally through Cana Laboratories, the agreement also strengthens the domestic supply chain, making it more resilient to the global disruptions that have plagued the pharmaceutical industry in recent years.

Capitalizing on the European Generics Market

The PathMuscle deal also places Cosmos Health at the forefront of a major trend in the European pharmaceutical industry: the growing reliance on high-quality, cost-effective generic medicines. In Greece, the market for generics has shown robust growth, with a reported 5.7% rise in value in 2024. This trend is fueled by healthcare systems and patients alike seeking affordable alternatives to originator brands without compromising on therapeutic efficacy.

As an "advanced generic," PathMuscle fits perfectly into this market dynamic. It provides a proven therapeutic solution in a modern formulation, offering value to the healthcare system. The agreement positions Cosmos Health not just as a brand owner but as a pivotal player in the broader healthcare ecosystem through its role as a contract manufacturing organization (CMO). As pharmaceutical companies increasingly look to outsource production to streamline operations and reduce costs, certified and reliable CMOs like Cana Laboratories become indispensable partners.

This move aligns with the broader growth of the Greek pharmaceutical sector, which has been expanding its export capabilities and attracting significant investment. By securing a long-term, high-volume contract, Cosmos Health is capitalizing on this momentum and deepening its roots in a key European market.

Financial Strength and Future Outlook

For Cosmos Health and its investors, this agreement provides a clear and predictable revenue stream for the next half-decade. The minimum commitment of nearly 600,000 units, with an expected total exceeding 1.2 million, underpins the company's financial projections and supports the efficient use of its manufacturing capacity. This comes on the heels of strong financial performance, including a reported 37.86% year-over-year revenue increase in the third quarter of 2025, and this deal is set to sustain that growth trajectory.

Beyond the immediate financial impact, the agreement serves as a powerful endorsement of Cana Laboratories' capabilities. Successfully delivering on this contract will further burnish its reputation and could attract additional CMO partnerships from other pharmaceutical companies operating in Europe. It validates the company's diversified strategy, which balances proprietary brand development, telehealth services, and a robust manufacturing arm. This strategic partnership not only aims to capture a significant share of the musculoskeletal treatment market in Greece but also solidifies Cosmos Health's standing as a versatile and indispensable player in the international pharmaceutical landscape.